Group 1: Company Highlights - Above Food Ingredients Inc. Warrants (OTC:ABVEW) leads the market with an 81.74% increase, reaching $0.69, focusing on disruptive agriculture and international operations in sustainable food [1][7] - SMX (NASDAQ:SMX) follows with a 74.64% rise to $33.67, known for its brand protection and authentication technology, benefiting from innovative anti-counterfeit solutions and a strong financial outlook for 2026 [2][7] - Bristol-Myers Squibb Company Ce (CELG-RI) saw a 71.53% increase to $0.11, driven by advancements in small molecules and biologics, emphasizing drug manufacturing and healthcare treatments [3] - EUDA Health Holdings Limited (EUDAW) experienced a 67.29% rise to $0.12, focusing on virtual consults for non-emergency medical issues, gaining traction in the digital health sector [4] - Momentus Inc. (NASDAQ:MNTS) saw a 61.75% increase to $15.9, specializing in space transportation and in-orbit servicing, supported by industry developments and a recent $5 million private placement [5][7] Group 2: Industry Trends - The market is witnessing dynamic movements with sectors like sustainable food and space exploration capturing investor interest, highlighting the importance of unique industry positions and strategic developments [6]

36项重大科技创新成果集中亮相 过去7年，湖北一直把科技创新摆在突出位置，每年第一个工作日会召开全省科技创新大会。2024年， 湖北省委、省政府以结果为导向，开创性提出建设"61020"科技创新体系，即每年产出6项重大基础研究 成果，突破10项重大关键技术，形成20项标志性产品。"61020"科技创新成果体系与湖北省"51020"现代 产业集群建设、"71020"高校学科创新体系形成系统性制度创新。 基础研究是科技创新的源头活水，6项成果中，华中农业大学李一博教授团队发现水稻抗高温关键基因 QT12，在长江流域高温期田间试验中最高增产78%且米质达国标二级，成果入选《科学》2025年度十 大科学突破；武汉大学宋威教授团队首次阐明癌症恶病质由"肿瘤—胰肾轴"引发，颠覆国际传统认知； 华中科技大学夏宝玉教授团队实现二氧化碳电催化制甲酸连续稳定运行超5000小时，碳利用率超90%。 一批关键核心技术取得重大突破。湖北九峰山实验室开发国内首个100nm硅基氮化镓射频PDK，完成芯 片小批量试制；华中科技大学丁烈云院士团队研发智能盾构自适应控制技术，全球首次实现"边挖掘、 边拼装、不停机"；湖北东湖实验室李卫超教授团队 ...

Core Viewpoint - CDT Equity Inc. has engaged NJS Foresight Bio-Advisory to enhance its out-licensing opportunities for its solid-form patent portfolio, aiming to expand commercial reach and accelerate licensing transactions [1][4]. Group 1: Company Strategy and Engagement - The engagement with NJS Foresight Bio-Advisory is focused on identifying and supporting out-licensing opportunities for selected assets within CDT's solid-form patent portfolio [1]. - NJS Foresight Bio-Advisory has over 20 years of experience in out-licensing and has successfully completed numerous agreements in the biotechnology and pharmaceutical sectors [2]. - Dr. Nicholas J. Sarlis, the principal of NJS Foresight, has extensive expertise in clinical and pharmaceutical development, having led teams in both early and late-stage programs and participated in over thirty clinical studies [2]. Group 2: Solid-Form Patent Portfolio - CDT's solid-form patent portfolio includes cocrystals and salts that provide enhanced physicochemical properties, such as improved solubility and bioavailability, with up to twenty years of patent protection [3]. - The company is actively exploring opportunities where marketed products face significant patent cliffs, leveraging its differentiated solid-forms of active pharmaceutical ingredients [4]. Group 3: Market Environment and Future Outlook - Industry data indicates a renewed investment activity in biopharma, driven by patent expirations, strategic consolidation, and the adoption of AI technologies, creating a favorable environment for solid-form innovation and out-licensing [4]. - CDT's CEO, Dr. Andrew Regan, emphasized the strong potential for solid-form assets to support lifecycle management strategies across the sector [5]. Group 4: Company Overview - CDT Equity Inc. is a biopharmaceutical development company focused on enhancing high-potential therapeutic assets through scientific innovation and strategic partnerships [6]. - The company has implemented a cryptocurrency treasury reserve strategy, initially focused on Bitcoin, to diversify capital allocation and strengthen its financial position [6].

U.S. stocks traded lower midway through trading, with the Nasdaq Composite falling more than 100 points on Monday.The Dow traded down 0.43% to 48,500.27 while the NASDAQ slipped 0.52% to 23,470.77. The S&P 500 also fell, dropping, 0.34% to 6,906.49.Check This Out: Top 2 Risk Off Stocks That May Collapse In DecemberLeading and Lagging SectorsEnergy shares rose by 1.1% on Monday.In trading on Friday, materials stocks fell by 1.3%.Top HeadlineU.S. pending home sales jumped by 3.3% month-over-month in November, ...

U.S. stocks traded lower midway through trading, with the Nasdaq Composite falling more than 100 points on Monday.The Dow traded down 0.43% to 48,500.27 while the NASDAQ slipped 0.52% to 23,470.77. The S&P 500 also fell, dropping, 0.34% to 6,906.49.Check This Out: Top 2 Risk Off Stocks That May Collapse In DecemberLeading and Lagging SectorsEnergy shares rose by 1.1% on Monday.In trading on Friday, materials stocks fell by 1.3%.Top HeadlineU.S. pending home sales jumped by 3.3% month-over-month in November, ...

U.S. stocks traded lower this morning, with the Dow Jones index falling more than 100 points on Monday.Following the market opening Monday, the Dow traded down 0.25% to 48,591.37 while the NASDAQ slipped 0.55% to 23,464.42. The S&P 500 also fell, dropping, 0.34% to 6,906.41.Check This Out: Top 2 Risk Off Stocks That May Collapse In DecemberLeading and Lagging SectorsEnergy shares rose by 0.6% on Monday.In trading on Monday, materials stocks fell by 1.1%.Top HeadlineU.S. pending home sales jumped by 3.3% mon ...

The year’s run-up in precious metals broke new ground on Friday, while U.S. stocks held close to all-time highs. Most-active silver futures were up 4.5% at around $75 a troy ounce, after earlier hitting a new intraday record. A runaway rally in silver, which has more than doubled in price this year, has swept up amateur investors. Equivalent contracts for gold futures also hit records, rising as high as $4,562 a troy ounce. Most Read from The Wall Street Journal Escalating geopolitical tensions likely ...

Registrations OPEN thrd India's first of-its-kind, 6 Annual Summit on Biopharmaceutical Product Development in conjunction with the 3 edition of the International Conference on Advances in 3D Cell Culture. Date & Venue: January 22-23, 2026, | Novotel Dona Sylvia Resort, Goa, India MUMBAI, India and GOA, India, Dec. 17, 2025 /PRNewswire/ -- The Mumbai Biocluster, in association with the Institute of Chemical Technology, Mumbai, proudly announces Biologics X 3DCC Summit 2026 — a landmark unified summit that m ...

Core Insights - Soleno Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for rare diseases, currently not generating significant revenue [1] - The company operates in a sector characterized by a focus on research and development rather than immediate profitability [5] Financial Metrics - Soleno's Return on Invested Capital (ROIC) is -15.74%, with a Weighted Average Cost of Capital (WACC) of 4.67%, resulting in a ROIC to WACC ratio of -3.37, indicating it is not generating returns that exceed its cost of capital [2] - In comparison, Akari Therapeutics has a ROIC of -64.44% and a WACC of 3.75%, leading to a ROIC to WACC ratio of -17.18, while Leap Therapeutics shows a ROIC of -37.62% and a WACC of 4.69, with a ratio of -8.02 [3] - Tenax Therapeutics has the highest ROIC to WACC ratio among peers at -4.39, despite a ROIC of -48.59% and a WACC of 11.07, suggesting it is relatively closer to covering its cost of capital [4] Industry Overview - All companies in the peer group, including Soleno Therapeutics, are experiencing negative ROIC, which is typical for clinical-stage biopharmaceutical companies in the investment phase [5]

Keep your expectations in check.It now seems so long ago that Pfizer (PFE +0.50%) became the first company in the biopharmaceutical industry to generate over $100 billion in annual sales. The drugmaker achieved this milestone thanks to its dominance in the coronavirus vaccine market. However, this niche has since shrunk considerably -- and it could become even smaller next year. Regulators in the U.S. are making it harder for healthy individuals to get vaccinated.Pfizer needs a way to replace this dwindling ...